Background
Atrial fibrillation (AF) is one of the most critical and frequent arrhythmias precipitating morbidities and mortalities such as hemodynamic instability, thromboembolism, and stroke, increasing hospital re-admissions and, consequently, health care costs. In general, AF negatively affects patient quality of life [1] . AF alone is associated with 1.5% to 1.9% increase in risk of mortality in a wide spectrum of ages in both genders [2] . Moreover, the situation is likely to worsen since the number of people with AF is expected to double by 2050 [2, 3] .
The pathophysiological mechanism in AF is highly complex and multifactorial [3] . Prothrombotic state, inflammation, and oxidative stress may play important roles in the occurrence of supraventricular arrhythmia [4] . Introduction of practical and available diagnostic methods and their wider use allows for better identification of patients with new-onset or recurrent AF [3, 4] . Traditionally, the major focus in diagnosis and management of AF has been patient medical history, examination, and detection of AF and paroxysmal AF (PAF) using cardiac monitoring.
Complete blood count (CBC) is an important blood test routinely used in clinical practice for workup of cardiovascular diseases [5] . The relationship between blood parameters in CBC tests and clinical outcomes in patients with ST-segment elevation myocardial infarction has been well documented [5] . However, the diagnostic performance of blood parameters for AF, alone and in combination with other diseases, is still unknown.
Various studies have reported the association of hematological parameters with new-onset and recurrent AF, but the data have been largely inconclusive. This systematic review with meta-analysis sought to determine the strength of evidence in terms of the potential association between a large number of hematologic parameters that can be easily obtained using the CBC test and new-onset and recurrent AF.
Material and Methods

Literature search
A comprehensive literature search was conducted in electronic scientific databases (Medline/PubMed, Embase, Web of Science, and Google Scholar) from their inception through November 30, 2016 to identify relevant studies on the association between blood parameters in CBC tests and new-onset and recurrent AF. Predefined search terms were as follows:
"white blood cell count", "WBC", "leucocyte", "neutrophil to lymphocyte ratio", "NLR", "platelet count", "mean platelet volume", "MPV", "platelet distribution width" "PDW", "red blood cell count", "RBC count", "red blood cell distribution width", "RDW", and "atrial fibrillation" or "supraventricular arrhythmia". No restrictions were applied regarding sample size of studies, language, and time of publication. To assess additional studies not indexed in common databases, all retrieved references of the enrolled studies, recent published review articles, and meta-analyses were also checked.
Study selection
Studies were included in the analysis when they met the following criteria: 1) human subjects; 2) cohort or case-control studies; 3) comparative studies between AF and non-AF-cohorts in terms of blood parameters; 4) studies comparing patients with recurrent AF (re-occurrence of AF in patients with history of treatment with anti-arrhythmic or electrophysiological interventions for AF) with those with non-recurrent AF focusing on blood parameters. Manuscripts that did not undergo peer-review, abstracts from congress presentations only, and gray literature were not included.
Primary and secondary blood parameters
Platelet count, MPV, PDW, WBC count, NLR, RBC count, and RDW were considered primary blood parameters. MCV, MCHC, HCT, and Hb were defined as secondary parameters.
Data extraction and outcome measures
Six investigators (S.A-H-S, A.S, S.Y, T.L, M-P. S, and J-S. J) independently extracted the data. Discrepancies were resolved by a consensus standardized abstraction checklist used for recording data in each included study. Disagreements were discussed and resolved by senior authors (A.W, A.F-P, G.B.Z, G.D.S and H.C). The following items were extracted from the included studies: author name; publication year; country; study design; sample size; mean age; gender; coexistent cardiovascular diseases, and risk factors, such as diabetes mellitus, hypertension, and history of myocardial infarction; percentage of used anticoagulants; AF type; and details of blood parameters. In order to examine heterogeneity among trials, subgroup analyses of disparities in patients' characteristics were carried out for: (1) the era of publication (pre-2000 vs. post-2000); (2) geographical area (Asia, Europe, Africa, North-America, South-America, and Oceania); (3) study design (case-control vs. cohort); (4) sample size of studies (£300 vs. >300); (5) mean age (£60 vs. >60 years); (6) percentage of male patients (£70% vs. >70%); (7) presence of diabetes (£30% vs. >30%); (8) presence of hypertension (£70% vs. >70%); (9) cigarette smoking (£30% vs. >30%); (10) presence of myocardial infarction (£20% vs. >20%); (11) use of cardiovascular drugs, such as diuretics, angiotensin converting enzyme inhibitors, statins and beta-blockers (for each: £70% vs. >70%); (12) AF-classification (chronic vs. nonchronic); (13) type of AF (paroxysmal, persistent, permanent); and (12) anticoagulation (code-1: not receiving anticoagulants in both groups; code-2: all participants receiving anticoagulants in both groups; code-3: range of percentages between both groups >50%; code-4: range of percentages between both groups <50%; code-5: no information available about anticoagulation in both groups; and code-6: anticoagulation information not available for 1 group only).
Homogenization of extracted data
Continuous data are expressed as mean ± standard deviation (SD). For studies reporting interquartile ranges, the mean was estimated according to the formula [minimum+maximum+2(median)]/4 and SD was calculated based on the formula (maximum-minimum)/4 for groups with sample sizes of n £70 and (maximum-minimum)/6 for sample sizes of >70 [6] .
Quality assessment and statistical analysis
The Newcastle-Ottawa scale was independently used by 3 investigators (S.A-H-S, M.G, and L.M) to assess the quality of studies [7] . Total scores ranged from 0 (worst quality) to 9 (best quality) for case-control or cohort studies. Data were analyzed by STATA 11.0 using METAN and METABIAS modules. For noncategorical data, pooled effect size measured was the weighted mean difference (WMD) with 95% CI. P value of <0.1 for Q test or I 2 >50% showed significant heterogeneity among the studies. Heterogeneity among trials was examined by applying a random-effects model when indicated. Publication bias was assessed using the Begg tests. P value of <0.05 was considered statistically significant.
Results
Literature search strategy and included studies
Overall, 2150 studies were retrieved from the literature search and screened databases. We excluded 1179 studies (63.55%) after detailed evaluation during the first review due to unnecessary information (n=750), inadequate report of endpoints of interest (n=370), or report of non-matched data based on mean ±SD or median [minimum-maximum] (n=59). In total, 971 potentially relevant full-text articles were screened, with 70 studies being analyzed in the meta-analysis on new-onset AF and 23 studies on recurrent AF (Supplementary Table 1 ) .
/L (95% CI: -0.052 to 0.042; p=0.83, Figure 3) , with considerable heterogeneity among the studies (I 2 =87.2%; heterogeneity p<0.001).
NLR
A total of 1899 cases were selected from 10 studies, of which 677 were allocated to the AF group and 1222 to the SR group. The mean NLR was 3.56 in the AF group and 2.61 in the SR group (details in Tables 1 and 2 ). Pooled analysis showed that the NLR was remarkably higher in patients with AF compared to controls, with a WMD of 0.89 (95% CI: 0.79 to 0.99; p<0.001, Figure 4 ) using a random-effects model. There was significant heterogeneity among the studies (I 2 =93.6%; heterogeneity p<0.001).
RBC count
A total of 572 cases were included from 2 studies, of which 251 were allocated to the AF group and 321 to the SR group. The mean RBC count was 4.52×10 12 /L in the AF group and 4.39×10 12 /L in the SR group (details in Tables 1 and 2 ). Using a random-effects model, pooled analysis showed that the mean count of RBC was statistically higher in the AF group compared to the SR group, with a WMD of 0.28×10 12 /L (95% CI: 0.23 to 0.33; p<0.001). Significant heterogeneity was observed among the studies (I 2 =96.8%; heterogeneity p<0.001).
RDW
A total of 1631 cases were included from 8 studies, of which 577 were allocated to the AF group and 1054 to the SR group. The mean of RDW was 14.01% in the AF group and 13.28% in the SR group (details in Tables 1 and 2 ). Using a randomeffects model, pooled analysis revealed that RDW was significantly higher in the AF group than in the SR group, with a WMD of 0.61% (95% CI: 0.56 to 0.66; p<0.001, Figure 5 ). There was significant heterogeneity among the studies (I 2 =94.7%; heterogeneity p<0.001)
Secondary hematological parameters
MCHC was reported in 1 study, which was not included in the meta-analysis. According to pooled assessment analysis, the level of MCV (number of studies=4, WMD of -0.14 FL, 95% CI: -0.51 to 0.23; p=0.46 and I 2 =34%; heterogeneity p=0.2) and Hb (number of studies=27, WMD of 0.04 g/dL, 95% CI: -0.02 to 0.10; p=0.23 and I 2 =91.1%; heterogeneity p<0.001) were similar in both groups. Pooled analysis showed that HCT (number of studies=11, WMD of 1.79%, 95% CI: 1.43 to 2.15; p<0.001 and I 2 =80.6%%; heterogeneity p<0.001) was significantly higher in the AF group compared to the SR group. Table 2 continued. Information about markers and these levels in each study [77] Association of hematologic parameters with recurrent AF
Platelet count
A total of 696 cases were selected from 4 studies, of which 207 were allocated to recurrent AF group and 489 to the nonrecurrent AF group (details in Tables 1 and 2 ). Pooled effects analysis showed that the mean platelet count did not differ between groups, with a WMD of -2.71×10 9 /L (95% CI: -12.75 to 7.34; p=0.59). Significant heterogeneity was observed among the studies (I 2 =69.4%; heterogeneity p=0.02).
WBC
A total of 3716 patients were included from 22 studies, of which 1223 were allocated to the recurrent AF group and 2493 to the non-recurrent AF group (details in Tables 1 and 2 ). The mean WBC count was 6.89×10 9 /L in patients with recurrent AF and 6.79×10 9 /L in those with non-recurrent AF. Pooled analysis revealed that the mean count of WBC was statistically higher in the recurrent group compared to the non-recurrent group, with a WMD of 0.20×10 9 
NLR
A total of 1620 cases were selected from 7 studies, of which 446 were allocated to the recurrent AF group and 1174 to the non-recurrent AF group (details in Tables 1 and 2 ). Pooled assessment analysis indicated that the NLR was significantly higher in patients suffering from recurrent AF compared to the non-recurrent group, with a WMD of 0.37 (95% CI: 0.24 to 0.50; p<0.001, Figure 7 ). There was significant heterogeneity among the studies (I 2 =83.2%; heterogeneity p<0.001).
RDW
A total of 1209 cases were included from 5 studies, of which 423 were allocated to the recurrent AF group and 786 to the non-recurrent AF group (details in Tables 1 and 2 ). Using a random-effects model, pooled analysis revealed that RDW was considerably higher in the recurrent AF group than in the nonrecurrent group, with a WMD of 0.28% (95% CI: 0.18 to 0.38; p<0.001, Figure 8 ). There was significant heterogeneity among the studies (I 2 =87.5%; heterogeneity p<0.001).
Secondary hematological parameters
MCV and Hb were investigated in at least 2 studies, which were included in the meta-analysis. According to pooled assessment analysis, the levels of MCV (number of studies=2, WMD of 0.21, 95% CI: -0.43 to 0.85; p=0.52 and I 2 =1.6%; heterogeneity p=0.31) and Hb (number of studies=9, WMD of 0.04 g/dL, 95% CI: -0.12 to -0.19; p=0.64 and I 2 =13.6%; heterogeneity p=0.32) were similar in both groups. 
Other parameters
There was an insufficient number of studies for analysis on association between MPV, RBC count, and HCT and recurrent AF.
Publication bias and subgroup analysis
Begg tests suggested that all of the analyses were without publication bias except for association between Hb and recurrent AF. Extra details of characteristics of each study for exploration of heterogeneity factors are presented in Supplementary Discussion AF is one of the most common cardiac arrhythmias in developing and developed countries, precipitating morbidities and mortalities [78, 79] . Various mechanisms are involved in AF, such as inflammation, oxidative stress, and prothrombotic state [79, 80] . Therefore, the complications of this arrhythmia and their negative effects on quality of life can be decreased by more accurate recognition of mechanisms, timely diagnosis, and appropriate treatment. Although taking patient history, considering the history of cardiac arrhythmia, clinical examinations, ECG, and Holter monitoring can assist in diagnosis and control of AF, some routine diagnostic actions which are performed daily in clinical practice might be of higher value than previously thought [81] . CBC is a routine lab test for most patients, particularly those with cardiovascular diseases hospitalized in cardiology and cardiac surgery wards, as well as CCUs or ICUs [81] . Hematological parameters in CBC tests can indicate hemodynamic status and are appropriate predictors for clinical outcomes of these patients [81] . Varastehravan et al. reported that hematological parameters had considerable ability in prognosis of ST-segment resolution in patients with STsegment elevation myocardial infarction receiving streptokinase therapy [5] .
In the present study, we investigated the association of hematological parameters with new-onset and recurrent AF in order to understand which hematological parameters could be reliable predictors of each type of AF. Although the majority of physicians and researchers have believed that platelet count in cases with new-onset AF is higher than in patients with SR, our findings revealed that the number of platelets was significantly lower in cases with new-onset AF compared to those with SR, resulting in the likelihood of lower platelet count to predict new-onset AF.
Our subgroup analysis showed an inverse relationship between platelet count and new-onset AF in cases of persistent AF, but this relationship was not found in cases of paroxysmal and permanent AF. On the other hand, there was no significant relationship between platelet count and new-onset AF in patients with chronic AF. According to our findings, sample size of the studies, age, diabetes mellitus, differences regarding treatment with anticoagulants, and type of AF are factors of heterogeneity. The present study found no remarkable relationship between platelet count and recurrent AF; therefore, platelet count could be a potential predictor for new-onset AF, but it does not appear to be a significant factor associated with recurrent AF. Regarding the results of this study, PDW was considerably lower in cases with new-onset AF compared to those with SR. Thus, PDW and platelet count both had an inverse relationship with the new-onset AF.
MPV is known as an important biomarker of platelet activity. Large platelets secrete many critical mediators of coagulation, inflammation, thrombosis, and atherosclerosis. Evidence shows a close relationship between MPV and cardiovascular risk factors, such as diabetes mellitus, hypertension, and hypercholesterolemia [82, 83] . Interestingly, in a recent study, Sansanayudh et al. reported an association between MPV and coronary artery disease (CAD). Patients with CAD and slow coronary blood flow had larger MPV than in the control group. They concluded that MPV might be used for risk stratification or to raise diagnostic accuracy of the traditional risk stratification markers in CAD patients [84] .
The results of our study showed that MPV was also considerably higher in cases with new-onset AF compared to those with SR. According to our subgroup analysis, there was also a direct relationship between MPV and new-onset AF in both chronic and non-chronic AF. Sample sizes of the studies, differences in treatment with anticoagulants, and type of AF appeared to be factors of heterogeneity. Owing to insufficient number of studies on the association between PDW and MPV with recurrent AF, no analysis was performed in this regard.
There is a known relationship between inflammation and development of AF. Activities in hematopoietic tissues producing inflammatory leukocytes are closely associated with systemic inflammation, arterial inflammation, and cardiovascular events; however, their association with AF is unclear [85] .
The findings of this study demonstrated that WBC count was not significantly different between cases of new-onset AF compared to those of SR; therefore, WBC is not proposed as a reliable predictor. The present study also confirmed that WBC count was not associated with new-onset AF for chronic and non-chronic AF. Our subgroup analysis indicated that risk factors such as diabetes mellitus, hypertension, and cigarette smoking could be factors of heterogeneity. On the other hand, our results revealed that WBC count was statistically higher in cases of recurrent AF compared to those with non-recurrent AF. Consequently, it can be stated that WBC count might be considered a predictor for recurrent AF, but not for new-onset AF. It also implies that possible inflammatory mechanisms are more active in patients who develop recurrent AF despite antiarrhythmic therapy for AF. As a result, considering inflammatory markers as a valuable tool to detect the risk of recurrent AF after pharmacological interventions and electrophysiology could greatly help in terms of timely diagnosis of AF recurrence.
The neutrophil to lymphocyte ratio is a new systemic inflammatory marker and a prognostic indicator of cardiovascular diseases [86, 87] . The results of this study show that NLR is directly associated with new-onset and recurrent AF and generally could be an appropriate and efficient predictor for this disease. In our subgroup analysis, NLR also had this predictive ability for paroxysmal and persistent AF, while the association of NLR with permanent and chronic AF could not be detected due to the lack of relevant studies.
RDW is a parameter used to measure variability in the size of circulatory red blood cells obtained in CBC tests. Higher RDW reflects the presence of anisocytosis, which is associated with impaired erythropoiesis and RBC degradation appearing as chronic inflammation and a high level of oxidative stress [88] .
Several studies suggested that RDW can predict poor outcomes in patients with heart failure, stable CAD, and acute myocardial infarction [89] [90] [91] . Similarly, our study showed that RDW was clearly higher in cases with new-onset AF compared to cases with SR. However, RDW was significantly increased in patients with recurrent AF versus non-recurrent AF, providing strong evidence that RDW can predicting both new-onset and recurrent AF. Only 2 studies investigated RBC count and its impact on AF, in which pooled analysis showed that RBC count was statistically higher in the AF group than in the SR group. No study was found investigating the relationship between this hematological parameter and recurrent AF.
Anemia increases the risk of cardiovascular complications, such as thromboembolic events, bleeding, and mortality in anticoagulated patients with AF. Patients with anemia and AF are supposed to be closely monitored while under treatment with all types of anticoagulants [92] . In the present study, Hb, HCT, MCV, and MCHC were examined as secondary hematological parameters. Pooled analysis found no significant differences in Hb levels comparing cases of new-onset AF with cases of SR. Notably, our subgroup analysis showed that the status of treatment with anticoagulants was not defined in a significant number of studies. Therefore, we had no information on whether patients enrolled in these studies had been receiving anticoagulant therapy. Concerning general findings, it appears that Hb is not a potential predictor for new-onset AF; however, this might change in the future by defining the therapeutic strategies with anticoagulants as well as the number of patients under treatment. On the other hand, there was an interesting finding about the type of AF. When the studies were sorted in terms of chronic and non-chronic AF, the level of Hb was considerably higher in non-chronic AF and significantly lower in chronic AF. This finding suggests that the type of AF in terms of acute or chronic pattern might have different effects on Hb changes. The merged results rejected any relationship between Hb and new-onset AF; however, based on our subgroup analysis, we believe that after categorizing the types of AF into chronic and non-chronic, Hb might be a predictor. The results also indicated that the level of Hb was similar in patients with recurrent AF and those with nonchronic AF. Performing subgroup analysis, we found that the lack of association of Hb changes with recurrent AF was not influenced by any factor. Therefore, we strongly corroborate the lack of association between this hematological parameter and recurrent AF.
MCV is a measure of the average red blood cell. Based on our results, the level of MCV did not significantly differ between cases of new-onset AF versus SR cases, thus MCV could not be suggested as a predictor for new-onset AF. Also, our subgroup analysis strongly supported this finding.
Only 2 studies investigated the association of MCV and recurrent AF, and the merged analysis showed that the level of MCV was not significantly related to new-onset AF. HCT is a test for measuring the volume of RBC in relation to the total volume of blood. In the present study, the percentage of HCT was notably higher in cases of new-onset AF versus SR cases. Our subgroup analysis revealed that HCT can predict new-onset AF in non-chronic AF, but this ability was not seen in chronic AF. Due to the insufficient number of studies, we were unable to evaluate the relationship between HCT and recurrent AF.
Lip et al. reported that anticoagulants can reduce the level of hemostatic and hematologic factors in AF patients and, consequently, differences in treatment strategies with anticoagulants in various studies could be considered as a factor of heterogeneity [93] [94] [95] . Our subgroup analysis of platelet count, RDW, MCV, HCT, and WBC indicated that differences in using anticoagulants could play a considerable role in the existence of heterogeneity.
It should also be noted that in the meta-analysis on non-experimental studies, more heterogeneity was found, which can be explained by the following: 1) less controlled biases; 2) more confounding factors; and 3) differences in defining outcomes. Millions of CBC tests are performed daily for a large number of hospitalized patients with cardiovascular diseases throughout the world. In the present study, we found that CBC tests, apart from their ability to show a number of various pathologies already well known in clinical practice, might also play a significant role in diagnosis of various types of cardiac arrhythmias. Therefore, in addition to taking patient history, ECG, and Holter monitoring, the information from CBC in terms of AF should also be taken into account as an important diagnostic parameter. Therefore, we should be aware that, despite being one the most routine laboratory tests, the usefulness of CBC should not be underestimated.
Conclusions
Indeed, according to the results of previous research on potential predictive role of various CBC tests on the occurrence of AF that were conglomerated in our meta-analysis, CBC tests are a relatively easy to use and inexpensive tool to provide additional information on potential AF. Although CBC testing cannot replace standard diagnostics, they may be a valuable method to get some additional information in clinical diagnostics. In general, considering the results of this study, we conclude that lower platelet count and PDW, as well as higher MPV, NLR, RBC, RDW, and HTC, could be associated with new-onset AF. We strongly emphasize that MPV, NLR, and RDW have better predictive value in clinical practice for AF. Patients with AF who are under treatment are at high risk of recurrent AF; as a result, CBC is of particular importance for these patients. Our results also indicated that WBC, NLR, and PDW are hematological parameters with significant ability to predict recurrent AF. Therefore, emphasizing the potential predictive role of hematological parameters for new-onset and recurrent AF, we strongly recommend adding CBC testing to the diagnostic modalities of AF in clinical practice. Type of AF Paroxysmal Persistent Permanent
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